Drugs in preclinical and early-stage clinical development for pancreatic cancer

Bibliography

• Ghadirian P, Lynch HT, Krewski D. Epidemiology of pancreatic cancer: an overview. Cancer Detect Prev 2003;27:87-93
   PubMedGoogle Scholar
• Inoue M, Yamamoto S, Kurahashi N, Daily total physical activity level and total cancer risk in men and women: results from a large-scale population-based cohort study in Japan. Am J Epidemiol 2008;168:391-403
   PubMed Web of Science ®Google Scholar
• Mysliwiec P, Kedra B. Causes of delayed diagnosis of pancreatic cancer. Own study and proposed algorithm. Przegl Lek 2008;65:345-8
   PubMedGoogle Scholar
• Dhayat S, Mardin WA, Mees ST, Haier J. Epigenetic markers for chemosensitivity and chemoresistance in pancreatic cancer–a review. Int J Cancer 2011;129:1031-41
   PubMed Web of Science ®Google Scholar
• Tranah GJ, Holly EA, Wang F, Bracci PM. Cigarette, cigar and pipe smoking, passive smoke exposure, and risk of pancreatic cancer: a population-based study in the San Francisco Bay Area. BMC Cancer 2011;11:138
   PubMedGoogle Scholar
• Lowenfels AB, Maisonneuve P, DiMagno EP, Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst 1997;89:442-6
   PubMed Web of Science ®Google Scholar
• Danes BS, Lynch HT. A familial aggregation of pancreatic cancer. An in vitro study. JAMA 1982;247:2798-802
   PubMed Web of Science ®Google Scholar
• Lynch HT, Fitzsimmons ML, Smyrk TC, Familial pancreatic cancer: clinicopathologic study of 18 nuclear families. Am J Gastroenterol 1990;85:54-60
   PubMed Web of Science ®Google Scholar
• Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004;4:579-91
   PubMed Web of Science ®Google Scholar
• Cowgill SM, Muscarella P. The genetics of pancreatic cancer. Am J Surg 2003;186:279-86
   PubMed Web of Science ®Google Scholar
• Lochan R, Daly AK, Reeves HL, Charnley RM. Family history of cancer and tobacco exposure in index cases of pancreatic ductal adenocarcinoma. J Oncol 2011;2011:215985
   PubMedGoogle Scholar
• Shi C, Hruban RH, Klein AP. Familial pancreatic cancer. Arch Pathol Lab Med 2009;133:365-74
   PubMed Web of Science ®Google Scholar
• Grover S, Syngal S. Hereditary pancreatic cancer. Gastroenterology 2010;139:1076-80. 1080
   PubMed Web of Science ®Google Scholar
• Kastrinos F, Mukherjee B, Tayob N, Risk of pancreatic cancer in families with Lynch syndrome. JAMA 2009;302:1790-5
   PubMed Web of Science ®Google Scholar
• Kluijt I, Cats A, Fockens P, Atypical familial presentation of FAMMM syndrome with a high incidence of pancreatic cancer: case finding of asymptomatic individuals by EUS surveillance. J Clin Gastroenterol 2009;43:853-7
   PubMed Web of Science ®Google Scholar
• Naderi A, Couch FJ. BRCA2 and pancreatic cancer. Int J Gastrointest Cancer 2002;31:99-106
   PubMedGoogle Scholar
• Tokura M, Kamisawa T, Kuwata G, Pancreatic cancer as the fourth cancer in a patient with Peutz-Jeghers syndrome and a history of familial pancreatic cancer. Pancreas 2011;40:169-70
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Chapman PB, Feilchenfeldt J, Targeting mutated K-ras in pancreatic adenocarcinoma using an adjuvant vaccine. Am J Clin Oncol 2011;34:321-5
   PubMed Web of Science ®Google Scholar
• Brody JR, Costantino CL, Potoczek M, Adenosquamous carcinoma of the pancreas harbors KRAS2, DPC4 and TP53 molecular alterations similar to pancreatic ductal adenocarcinoma. Mod Pathol 2009;22:651-9
   PubMed Web of Science ®Google Scholar
• Li J, Weghorst CM, Tsutsumi M, Frequent p16INK4A/CDKN2A alterations in chemically induced Syrian golden hamster pancreatic tumors. Carcinogenesis 2004;25:263-8
   PubMed Web of Science ®Google Scholar
• Grant WB, Mohr SB. Ecological studies of ultraviolet B, vitamin D and cancer since 2000. Ann Epidemiol 2009;19:446-54
   PubMed Web of Science ®Google Scholar
• Kinoshita S, Wagatsuma Y, Okada M. Geographical distribution for malignant neoplasm of the pancreas in relation to selected climatic factors in Japan. Int J Health Geogr 2007;6:34
   PubMed Web of Science ®Google Scholar
• Raimondi S, Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic cancer: an overview. Nat Rev Gastroenterol Hepatol 2009;6:699-708
   PubMed Web of Science ®Google Scholar
• Rosewicz S, Wiedenmann B. Pancreatic carcinoma. Lancet 1997;349:485-9
   PubMed Web of Science ®Google Scholar
• Long J, Zhang Y, Yu X, Overcoming drug resistance in pancreatic cancer. Expert Opin Ther Targets 2011;15:817-28
   PubMed Web of Science ®Google Scholar
• Lockhart AC, Rothenberg ML, Berlin JD. Treatment for pancreatic cancer: current therapy and continued progress. Gastroenterology 2005;128:1642-54
   PubMed Web of Science ®Google Scholar
• Meriggi F, Forni E. Extended lymphadenectomy for carcinoma of pancreatic head. Personal experience. G Chir 2002;23:383-90
   PubMedGoogle Scholar
• Yeo CJ, Abrams RA, Grochow LB, Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 1997;225:621-33
   PubMed Web of Science ®Google Scholar
• Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985;120:899-903
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Raraty MG, Ghaneh P, Adjuvant and additive therapy for cancer of the pancreas. Chirurg 2003;74:191-201
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Stocken DD, Dunn JA, Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 2001;234:758-68
   PubMed Web of Science ®Google Scholar
• Stocken DD, Buchler MW, Dervenis C, Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer 2005;92:1372-81
   PubMed Web of Science ®Google Scholar
• Boeck S, Ankerst DP, Heinemann V. The role of adjuvant chemotherapy for patients with resected pancreatic cancer: systematic review of randomized controlled trials and meta-analysis. Oncology 2007;72:314-21
   Google Scholar
• Drudi F, Tassinari DCC, Carloni FSC, Adjuvant treatments in pancreatic cancer: Preliminary data of a pooled analysis. J Clin Oncol 2011;29(Suppl):abstract #4042
   Google Scholar
• Khanna A, Walker GR, Livingstone AS, Is adjuvant 5-FU-based chemoradiotherapy for resectable pancreatic adenocarcinoma beneficial? A meta-analysis of an unanswered question. J Gastrointest Surg 2006;10:689-97
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Stocken DD, Tudur SC, Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials. Br J Cancer 2009;100:246-50
   PubMed Web of Science ®Google Scholar
• Oettle H, Post S, Neuhaus P, Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007;297:267-77
   PubMed Web of Science ®Google Scholar
• Richter J, Saif MW. Updates in adjuvant therapy in pancreatic cancer: gemcitabine and beyond. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium"; 22 – 24 January 2010; Orlando, FL, USA. JOP 2010;11:144-7
   Google Scholar
• Sawaki A, Hoki N, Ito S, Clinical impact of radiotherapy for locally advanced pancreatic cancer. J Gastroenterol 2009;44:1209-14
   PubMed Web of Science ®Google Scholar
• Moore MJ, Goldstein D, Hamm J, Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-6
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Stocken DD, Bassi C, Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010;304:1073-81
   PubMed Web of Science ®Google Scholar
• Hirao K, Kawamoto H, Sakakihara I, A 4-week versus a 3-week schedule of gemcitabine monotherapy for advanced pancreatic cancer: a randomized phase II study to evaluate toxicity and dose intensity. Int J Clin Oncol 2011;16(6):637-45
   PubMed Web of Science ®Google Scholar
• Gong JF, Zhang XD, Li J, Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer. Ai Zheng 2007;26:890-4
   PubMedGoogle Scholar
• Assaf E, Verlinde-Carvalho M, Delbaldo C, 5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma. Oncology 2011;80:301-6
   PubMed Web of Science ®Google Scholar
• Lowery MA, O'Reilly EM. New approaches to the treatment of pancreatic cancer: from tumor-directed therapy to immunotherapy. BioDrugs 2011;25:207-16
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817-25
   PubMed Web of Science ®Google Scholar
• Oberstein PE, Saif MW. First-line treatment for advanced pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium"; 20 – 22 January 2011; San Francisco, CA, USA. JOP 2011;12:96-100
   Google Scholar
• Chan E, Mulkerin D, Rothenberg M, A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas. Invest New Drugs 2008;26:241-7
   PubMed Web of Science ®Google Scholar
• Patterson AV, Ferry DM, Edmunds SJ, Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104. Clin Cancer Res 2007;13:3922-32
   PubMed Web of Science ®Google Scholar
• Mornex F, Girard N, Scoazec JY, Feasibility of preoperative combined radiation therapy and chemotherapy with 5-fluorouracil and cisplatin in potentially resectable pancreatic adenocarcinoma: the French SFRO-FFCD 97-04 Phase II trial. Int J Radiat Oncol Biol Phys 2006;65:1471-8
   PubMed Web of Science ®Google Scholar
• Bhutia YD, Hung SW, Patel B, CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells. Cancer Res 2011;71:1825-35
   PubMed Web of Science ®Google Scholar
• Sahai E, Marshall CJ. RHO-GTPases and cancer. Nat Rev Cancer 2002;2:133-42
   PubMed Web of Science ®Google Scholar
• DerMardirossian C, Bokoch GM. GDIs: central regulatory molecules in Rho GTPase activation. Trends Cell Biol 2005;15:356-63
   PubMed Web of Science ®Google Scholar
• Koide N, Yamada T, Shibata R, Establishment of perineural invasion models and analysis of gene expression revealed an invariant chain (CD74) as a possible molecule involved in perineural invasion in pancreatic cancer. Clin Cancer Res 2006;12:2419-26
   PubMed Web of Science ®Google Scholar
• Groysman M, Hornstein I, Alcover A, Katzav S. Vav1 and Ly-GDI two regulators of Rho GTPases, function cooperatively as signal transducers in T cell antigen receptor-induced pathways. J Biol Chem 2002;277:50121-30
   PubMed Web of Science ®Google Scholar
• Fernandez-Zapico ME, Gonzalez-Paz NC, Weiss E, Ectopic expression of VAV1 reveals an unexpected role in pancreatic cancer tumorigenesis. Cancer Cell 2005;7:39-49
   PubMed Web of Science ®Google Scholar
• Miyashita K, Nakada M, Shakoori A, An emerging strategy for cancer treatment targeting aberrant glycogen synthase kinase 3 beta. Anticancer Agents Med Chem 2009;9:1114-22
   PubMed Web of Science ®Google Scholar
• Hilbig A. Src kinase and pancreatic cancer. Recent Results Cancer Res 2008;177:179-85
   PubMedGoogle Scholar
• Boyer B, Valles AM, Edme N. Induction and regulation of epithelial-mesenchymal transitions. Biochem Pharmacol 2000;60:1091-9
   PubMed Web of Science ®Google Scholar
• Park SI, Shah AN, Zhang J, Gallick GE. Regulation of angiogenesis and vascular permeability by Src family kinases: opportunities for therapeutic treatment of solid tumors. Expert Opin Ther Targets 2007;11:1207-17
   PubMed Web of Science ®Google Scholar
• Messersmith WA, Rajeshkumar NV, Tan AC, Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts. Mol Cancer Ther 2009;8:1484-93
   PubMed Web of Science ®Google Scholar
• Duxbury MS, Ito H, Benoit E, CEACAM6 is a determinant of pancreatic adenocarcinoma cellular invasiveness. Br J Cancer 2004;91:1384-90
   PubMed Web of Science ®Google Scholar
• Strickland LA, Ross J, Williams S, Preclinical evaluation of carcinoembryonic cell adhesion molecule (CEACAM) 6 as potential therapy target for pancreatic adenocarcinoma. J Pathol 2009;218:380-90
   Google Scholar
• Duxbury MS, Ito H, Ashley SW, Whang EE. c-Src-dependent cross-talk between CEACAM6 and alphavbeta3 integrin enhances pancreatic adenocarcinoma cell adhesion to extracellular matrix components. Biochem Biophys Res Commun 2004;317:133-41
   PubMed Web of Science ®Google Scholar
• Duxbury MS, Ito H, Benoit E, Overexpression of CEACAM6 promotes insulin-like growth factor I-induced pancreatic adenocarcinoma cellular invasiveness. Oncogene 2004;23:5834-42
   PubMed Web of Science ®Google Scholar
• Duxbury MS, Ito H, Benoit E, A novel role for carcinoembryonic antigen-related cell adhesion molecule 6 as a determinant of gemcitabine chemoresistance in pancreatic adenocarcinoma cells. Cancer Res 2004;64:3987-93
   PubMed Web of Science ®Google Scholar
• Duxbury MS, Ito H, Zinner MJ, CEACAM6 gene silencing impairs anoikis resistance and in vivo metastatic ability of pancreatic adenocarcinoma cells. Oncogene 2004;23:465-73
   PubMed Web of Science ®Google Scholar
• Duxbury MS, Ito H, Ashley SW, Whang EE. CEACAM6 as a novel target for indirect type 1 immunotoxin-based therapy in pancreatic adenocarcinoma. Biochem Biophys Res Commun 2004;317:837-43
   PubMed Web of Science ®Google Scholar
• Kashiwaya K, Hosokawa M, Eguchi H, Identification of C2orf18, termed ANT2BP (ANT2-binding protein), as one of the key molecules involved in pancreatic carcinogenesis. Cancer Sci 2009;100:457-64
   PubMed Web of Science ®Google Scholar
• Gorantla B, Asuthkar S, Rao JS, Suppression of the uPAR-uPA system retards angiogenesis, invasion, and in vivo tumor development in pancreatic cancer cells. Mol Cancer Res 2011;9:377-89
   PubMed Web of Science ®Google Scholar
• He Y, Liu XD, Chen ZY, Interaction between cancer cells and stromal fibroblasts is required for activation of the uPAR-uPA-MMP-2 cascade in pancreatic cancer metastasis. Clin Cancer Res 2007;13:3115-24
   PubMed Web of Science ®Google Scholar
• Bauer TW, Liu W, Fan F, Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice. Cancer Res 2005;65:7775-81
   PubMed Web of Science ®Google Scholar
• Hildenbrand R, Niedergethmann M, Marx A, Amplification of the urokinase-type plasminogen activator receptor (uPAR) gene in ductal pancreatic carcinomas identifies a clinically high-risk group. Am J Pathol 2009;174:2246-53
   PubMed Web of Science ®Google Scholar
• Xue A, Scarlett CJ, Jackson CJ, Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma. Pancreas 2008;36:160-7
   PubMed Web of Science ®Google Scholar
• Chandrasekar N, Mohanam S, Gujrati M, Downregulation of uPA inhibits migration and PI3k/Akt signaling in glioblastoma cells. Oncogene 2003;22:392-400
   PubMed Web of Science ®Google Scholar
• Huang GJ, Yang CM, Chang YS, Hispolon suppresses SK-Hep1 human hepatoma cell metastasis by inhibiting matrix metalloproteinase-2/9 and urokinase-plasminogen activator through the PI3K/Akt and ERK signaling pathways. J Agric Food Chem 2010;58:9468-75
   PubMed Web of Science ®Google Scholar
• Huang HY, Jiang ZF, Li QX, Inhibition of human breast cancer cell invasion by siRNA against urokinase-type plasminogen activator. Cancer Invest 2010;28:689-97
   PubMed Web of Science ®Google Scholar
• Lai KC, Huang AC, Hsu SC, Benzyl isothiocyanate (BITC) inhibits migration and invasion of human colon cancer HT29 cells by inhibiting matrix metalloproteinase-2/-9 and urokinase plasminogen (uPA) through PKC and MAPK signaling pathway. J Agric Food Chem 2010;58:2935-42
   PubMed Web of Science ®Google Scholar
• Uchima Y, Sawada T, Hirakawa K. Action of antiproteases on pancreatic cancer cells. JOP 2007;8:479-87
   PubMedGoogle Scholar
• Clarke MF, Fuller M. Stem cells and cancer: two faces of eve. Cell 2006;124:1111-15
   PubMed Web of Science ®Google Scholar
• Subramaniam D, Ramalingam S, Houchen CW, Anant S. Cancer stem cells: a novel paradigm for cancer prevention and treatment. Mini Rev Med Chem 2010;10:359-71
   PubMed Web of Science ®Google Scholar
• Katari UL, Keirnan JM, Worth AC, Engineered T cells for pancreatic cancer treatment. HPB (Oxford) 2011;13:643-50
   PubMed Web of Science ®Google Scholar
• Shankar S, Nall D, Tang SN, Resveratrol inhibits pancreatic cancer stem cell characteristics in human and KrasG12D transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition. PLoS One 2011;6:e16530
   PubMed Web of Science ®Google Scholar
• Lee CJ, Dosch J, Simeone DM. Pancreatic cancer stem cells. J Clin Oncol 2008;26:2806-12
   PubMed Web of Science ®Google Scholar
• Lou H, Dean M. Targeted therapy for cancer stem cells: the patched pathway and ABC transporters. Oncogene 2007;26:1357-60
   PubMed Web of Science ®Google Scholar
• Morton JP, Mongeau ME, Klimstra DS, Sonic hedgehog acts at multiple stages during pancreatic tumorigenesis. Proc Natl Acad Sci USA 2007;104:5103-8
   PubMed Web of Science ®Google Scholar
• Thayer SP, di Magliano MP, Heiser PW, Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 2003;425:851-6
   PubMed Web of Science ®Google Scholar
• Chun SG, Zhou W, Yee NS. Combined targeting of histone deacetylases and hedgehog signaling enhances cytoxicity in pancreatic cancer. Cancer Biol Ther 2009;8:1328-39
   PubMed Web of Science ®Google Scholar
• Tiede S, Paus R. Lhx2–decisive role in epithelial stem cell maintenance, or just the "tip of the iceberg"? Bioessays 2006;28:1157-60
   PubMed Web of Science ®Google Scholar
• Gutova M, Najbauer J, Frank RT, Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors. Stem Cells 2008;26:1406-13
   PubMed Web of Science ®Google Scholar
• Carthew RW, Sontheimer EJ. Origins and Mechanisms of miRNAs and siRNAs. Cell 2009;136:642-55
   PubMed Web of Science ®Google Scholar
• Bloomston M, Frankel WL, Petrocca F, MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 2007;297:1901-8
   PubMed Web of Science ®Google Scholar
• Iorio MV, Croce CM. MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol 2009;27:5848-56
   PubMed Web of Science ®Google Scholar
• Lee EJ, Gusev Y, Jiang J, Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer 2007;120:1046-54
   PubMed Web of Science ®Google Scholar
• Szafranska AE, Doleshal M, Edmunds HS, Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues. Clin Chem 2008;54:1716-24
   PubMed Web of Science ®Google Scholar
• Asangani IA, Rasheed SA, Nikolova DA, MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008;27:2128-36
   PubMed Web of Science ®Google Scholar
• Gabriely G, Wurdinger T, Kesari S, MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol Cell Biol 2008;28:5369-80
   PubMed Web of Science ®Google Scholar
• Moriyama T, Ohuchida K, Mizumoto K, MicrRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance. Mol Cancer Ther 2009;8:1067-74
   PubMed Web of Science ®Google Scholar
• Roldo C, Missiaglia E, Hagan JP, MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol 2006;24:4677-84
   PubMed Web of Science ®Google Scholar
• Meng F, Henson R, Lang M, Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 2006;130:2113-29
   PubMed Web of Science ®Google Scholar
• Park JK, Lee EJ, Esau C, Schmittgen TD. Antisense inhibition of microRNA-21 or -221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma. Pancreas 2009;38:e190-9
   PubMed Web of Science ®Google Scholar
• Jung DE, Wen J, Oh T, Song SY. Differentially expressed MicroRNAs in pancreatic cancer stem cells. Pancreas 2011; Epub ahead of print
   Web of Science ®Google Scholar
• Krichevsky AM, Gabriely G. miR-21: a small multi-faceted RNA. J Cell Mol Med 2009;13:39-53
   PubMed Web of Science ®Google Scholar
• Preis M, Gardner TB, Gordon SR, MicroRNA-10b Expression correlates with response to neoadjuvant therapy and survival in pancreatic ductal adenocarcinoma. Clin Cancer Res 2011;17:5812-21
   PubMed Web of Science ®Google Scholar